April 2017 - FRMC

Volume
14
Issue 4
April 2017

FEATURES

 Eileen Koutnik-Fotopoulos

As legal adoption of medical marijuana continues, questions regarding the variation in laws between states continue to challenge managed care professionals. | Read More
Citation:

Dean Celia

Michael S Barr, MD, discusses PCMH’s evolution, explains NCQA’s revised recognition program process, and reveals what practices can do now to get ready. | Read More
Citation:

Mary Beth Nierengarten

With a shift away from use of opioid medications, providers and payers are unsure which therapies warrant prescribing and covering. | Read More
Citation:

 Jill Sederstrom

Genomic testing is increasingly being used in clinical settings, but challenges in reimbursement and physician education impact the industry and slow down adoption. | Read More
Citation:

DEPARTMENTS

Researchers showed that a low dose of Xarelto reduced the risk of venous thromboembolism (VTE) in patients at high risk for a recurrence of blood clots. | Read More
Citation:
Treatment with sodium glucose cotransporter-2 (SGLT-2) inhibitors significantly reduced risk of hospitalization for heart failure and all-cause mortality. | Read More
Citation:
According to research, use of the PCSK9 inhibitor Repatha reduced the risk for death by lowering levels of low-density lipoprotein, also known as “bad cholesterol.” | Read More
Citation:
A study found that deployment of intranasal naloxone delivery devices in emergency overdose situations reduces the risk of death from opioid overdose. | Read More
Citation: